177 related articles for article (PubMed ID: 31949019)
1. Low-dose Btk inhibitors selectively block platelet activation by CLEC-2.
Nicolson PLR; Nock SH; Hinds J; Garcia-Quintanilla L; Smith CW; Campos J; Brill A; Pike JA; Khan AO; Poulter NS; Kavanagh DM; Watson S; Watson CN; Clifford H; Huissoon AP; Pollitt AY; Eble JA; Pratt G; Watson SP; Hughes CE
Haematologica; 2021 Jan; 106(1):208-219. PubMed ID: 31949019
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
[TBL] [Abstract][Full Text] [Related]
3. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.
Manne BK; Badolia R; Dangelmaier C; Eble JA; Ellmeier W; Kahn M; Kunapuli SP
J Biol Chem; 2015 May; 290(18):11557-68. PubMed ID: 25767114
[TBL] [Abstract][Full Text] [Related]
4. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
6. Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.
Hardy AT; Palma-Barqueros V; Watson SK; Malcor JD; Eble JA; Gardiner EE; Blanco JE; Guijarro-Campillo R; Delgado JL; Lozano ML; Teruel-Montoya R; Vicente V; Watson SP; Rivera J; Ferrer-Marín F
Thromb Haemost; 2018 Jun; 118(6):1009-1020. PubMed ID: 29695020
[TBL] [Abstract][Full Text] [Related]
7. Differential Regulation of GPVI-Induced Btk and Syk Activation by PKC, PKA and PP2A in Human Platelets.
Zhang P; Solari FA; Heemskerk JWM; Kuijpers MJE; Sickmann A; Walter U; Jurk K
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175486
[TBL] [Abstract][Full Text] [Related]
8. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
Hsu J; Gu Y; Tan SL; Narula S; DeMartino JA; Liao C
Immunol Lett; 2013 Feb; 150(1-2):97-104. PubMed ID: 23266841
[TBL] [Abstract][Full Text] [Related]
9. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
[TBL] [Abstract][Full Text] [Related]
11. Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function.
Tullemans BME; Karel MFA; Léopold V; Ten Brink MS; Baaten CCFMJ; Maas SL; de Vos AF; Eble JA; Nijziel MR; van der Vorst EPC; Cosemans JMEM; Heemskerk JWM; Claushuis TAM; Kuijpers MJE
EJHaem; 2021 Nov; 2(4):685-699. PubMed ID: 35845214
[TBL] [Abstract][Full Text] [Related]
12. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
13. Akt and mitogen-activated protein kinase enhance C-type lectin-like receptor 2-mediated platelet activation by inhibition of glycogen synthase kinase 3α/β.
Moroi AJ; Watson SP
J Thromb Haemost; 2015 Jun; 13(6):1139-50. PubMed ID: 25858425
[TBL] [Abstract][Full Text] [Related]
14. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases.
Harbi MH; Smith CW; Nicolson PLR; Watson SP; Thomas MR
Platelets; 2021 Jan; 32(1):29-41. PubMed ID: 33307909
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry.
Cheung HYF; Moran LA; Sickmann A; Heemskerk JWM; Garcia Á; Watson SP
Platelets; 2022 Nov; 33(8):1293-1300. PubMed ID: 35535424
[TBL] [Abstract][Full Text] [Related]
16. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.
Quek LS; Bolen J; Watson SP
Curr Biol; 1998 Oct; 8(20):1137-40. PubMed ID: 9778529
[TBL] [Abstract][Full Text] [Related]
17. Clustering extent-dependent differential signaling by CLEC-2 receptors in platelets.
Dangelmaier C; Vari HR; Wright M; Kostyak JC; Kunapuli SP
Res Pract Thromb Haemost; 2022 Mar; 6(3):e12710. PubMed ID: 35573643
[TBL] [Abstract][Full Text] [Related]
18. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
[TBL] [Abstract][Full Text] [Related]
19. Galectin-9 activates platelet ITAM receptors glycoprotein VI and C-type lectin-like receptor-2.
Zhi Z; Jooss NJ; Sun Y; Colicchia M; Slater A; Moran LA; Cheung HYF; Di Y; Rayes J; Poulter NS; Watson SP; Iqbal AJ
J Thromb Haemost; 2022 Apr; 20(4):936-950. PubMed ID: 34936188
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Tyrosine Phosphoproteomic Analysis Reveals Novel Components of the Platelet CLEC-2 Signaling Cascade.
Izquierdo I; Barrachina MN; Hermida-Nogueira L; Casas V; Morán LA; Lacerenza S; Pinto-Llorente R; Eble JA; de Los Ríos V; Domínguez E; Loza MI; Casal JI; Carrascal M; Abián J; García A
Thromb Haemost; 2020 Feb; 120(2):262-276. PubMed ID: 31901221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
